Artificial intelligence in pharma: between hype, hope, and fear

Save calendar entry
idalab GmbH

Potsdamer Str. 68

10785 Berlin

AI inspires hope to make drug development faster and cheaper, but also raises fears of bringing black-box algorithms close to human health.

 

While AI-native biotechs, their pharma partners, and excitable media hail the age of “AI-developed drugs,” it remains challenging to gauge the true potential of the technology, as results are mixed: some clinical successes, but also setbacks, such as recent cuts at BenevolentAI or the merger of Exscientia and Recursion.

In this talk, we will look beyond the hype and disentangle which AI applications promise immediate benefits (e.g. by automating mundane work), and which are the slower-burning but more transformative use cases, allowing scientists to explore the vast, untapped space of chemical and biological molecules and unknown disease-causing variants – coming closer to the ultimate goal of making drug development more creative, more personalized, and more successful.

Please find more information and the sign-up link here.